Commence Biologics holds exclusive, worldwide licenses to foundational intellectual property covering novel technologies to enhance the performance of mesenchymal stromal cells [MSCs]. These technologies include strengthening the anti-inflammatory effects of MSCs, increasing persistence, and reducing their cost of manufacture.
- The patent entitled “Compositions and methods for enhancing the therapeutic potential of stem cells” was filed 13 Mar 2014, and has been granted in Europe and Japan, with other countries pending. It has the designation WO/2014/140930.
- The patent application entitled “Methods for isolation and expansion of umbilical cord mesenchymal stem cells” was filed on 26 Jan 2017 and has the designation PCT/US2017/015105.
Companies may obtain licenses to Commence IP – both patented and trade secret – for internal research & commercialization of therapeutics, as well as for use in biofabrication and transplantation products or systems, by contacting us at firstname.lastname@example.org.